We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Advisory Panel Recommends Aegerion’s Lomitapide to Treat HoFH
FDA Advisory Panel Recommends Aegerion’s Lomitapide to Treat HoFH
October 19, 2012
Despite liver toxicity concerns, the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted 13–2 to recommend approval of Aegerion Pharmaceuticals’ lomitapide.